Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 124

1.

High pCO2 promotes coral primary production.

Biscéré T, Zampighi M, Lorrain A, Jurriaans S, Foggo A, Houlbrèque F, Rodolfo-Metalpa R.

Biol Lett. 2019 Jul 26;15(7):20180777. doi: 10.1098/rsbl.2018.0777. Epub 2019 Jul 24.

PMID:
31337291
2.

Thermal performance of scleractinian corals along a latitudinal gradient on the Great Barrier Reef.

Jurriaans S, Hoogenboom MO.

Philos Trans R Soc Lond B Biol Sci. 2019 Aug 5;374(1778):20180546. doi: 10.1098/rstb.2018.0546. Epub 2019 Jun 17.

3.

Dendritic cells potently purge latent HIV-1 beyond TCR-stimulation, activating the PI3K-Akt-mTOR pathway.

van Montfort T, van der Sluis R, Darcis G, Beaty D, Groen K, Pasternak AO, Pollakis G, Vink M, Westerhout EM, Hamdi M, Bakker M, van der Putten B, Jurriaans S, Prins JH, Jeeninga R, Thomas AAM, Speijer D, Berkhout B.

EBioMedicine. 2019 Apr;42:97-108. doi: 10.1016/j.ebiom.2019.02.014. Epub 2019 Feb 26.

4.

Acquisition of wild-type HIV-1 infection in a patient on pre-exposure prophylaxis with high intracellular concentrations of tenofovir diphosphate: a case report.

Hoornenborg E, Prins M, Achterbergh RCA, Woittiez LR, Cornelissen M, Jurriaans S, Kootstra NA, Anderson PL, Reiss P, de Vries HJC, Prins JM, de Bree GJ; Amsterdam PrEP Project team in the HIV Transmission Elimination AMsterdam Consortium (H-TEAM).

Lancet HIV. 2017 Nov;4(11):e522-e528. doi: 10.1016/S2352-3018(17)30132-7. Epub 2017 Sep 14.

PMID:
28919303
5.

From clinical sample to complete genome: Comparing methods for the extraction of HIV-1 RNA for high-throughput deep sequencing.

Cornelissen M, Gall A, Vink M, Zorgdrager F, Binter Š, Edwards S, Jurriaans S, Bakker M, Ong SH, Gras L, van Sighem A, Bezemer D, de Wolf F, Reiss P, Kellam P, Berkhout B, Fraser C, van der Kuyl AC; BEEHIVE Consortium.

Virus Res. 2017 Jul 15;239:10-16. doi: 10.1016/j.virusres.2016.08.004. Epub 2016 Aug 4.

6.

Sources of HIV infection among men having sex with men and implications for prevention.

Ratmann O, van Sighem A, Bezemer D, Gavryushkina A, Jurriaans S, Wensing A, de Wolf F, Reiss P, Fraser C; ATHENA observational cohort.

Sci Transl Med. 2016 Jan 6;8(320):320ra2. doi: 10.1126/scitranslmed.aad1863.

7.

Association between gp120 envelope V1V2 and V4V5 variable loop profiles in a defined HIV-1 transmission cluster.

Pollakis G, Baan E, van Werkhoven MB, Berkhout B, Bakker M, Jurriaans S, Paxton WA.

AIDS. 2015 Jun 19;29(10):1161-71. doi: 10.1097/QAD.0000000000000692.

PMID:
26035318
8.

Twelve-Month Antiretroviral Therapy Suppresses Plasma and Genital Viral Loads but Fails to Alter Genital Levels of Cytokines, in a Cohort of HIV-Infected Rwandan Women.

Ondoa P, Gautam R, Rusine J, Lutter R, Jurriaans S, Kootstra N, Karita E, van de Wijgert J.

PLoS One. 2015 May 26;10(5):e0127201. doi: 10.1371/journal.pone.0127201. eCollection 2015.

9.

Temporary treatment during primary HIV infection does not affect virologic response to subsequent long-term treatment.

Grijsen ML, Wit FW, Jurriaans S, Kroon FP, Schippers EF, Koopmans P, Gras L, Lange JM, Prins JM; Primo-SHM Study Group.

PLoS One. 2014 Apr 3;9(4):e89639. doi: 10.1371/journal.pone.0089639. eCollection 2014.

10.

Lactobacillus-dominated cervicovaginal microbiota associated with reduced HIV/STI prevalence and genital HIV viral load in African women.

Borgdorff H, Tsivtsivadze E, Verhelst R, Marzorati M, Jurriaans S, Ndayisaba GF, Schuren FH, van de Wijgert JH.

ISME J. 2014 Sep;8(9):1781-93. doi: 10.1038/ismej.2014.26. Epub 2014 Mar 6.

11.

High prevalence of hepatitis B virus dual infection with genotypes A and G in HIV-1 infected men in Amsterdam, the Netherlands, during 2000-2011.

van der Kuyl AC, Zorgdrager F, Hogema B, Bakker M, Jurriaans S, Back NK, Berkhout B, Zaaijer HL, Cornelissen M.

BMC Infect Dis. 2013 Nov 14;13:540. doi: 10.1186/1471-2334-13-540.

12.

Triple infection with HIV-1, HTLV-1 and Strongyloides stercoralis, rendering CD4+ T-cell counts a misleading entity.

Janssen S, Rossatanga EG, Jurriaans S, ten Berge IJ, Grobusch MP.

Antivir Ther. 2013;18(7):949-51. doi: 10.3851/IMP2692. Epub 2013 Oct 24.

PMID:
24152969
13.

Translational HIV-1 research: from routine diagnostics to new virology insights in Amsterdam, the Netherlands during 1983-2013.

van der Kuyl AC, Bakker M, Jurriaans S, Back NK, Pasternak AO, Cornelissen M, Berkhout B.

Retrovirology. 2013 Aug 28;10:93. doi: 10.1186/1742-4690-10-93. Review.

14.

Low primary and secondary HIV drug-resistance after 12 months of antiretroviral therapy in human immune-deficiency virus type 1 (HIV-1)-infected individuals from Kigali, Rwanda.

Rusine J, Asiimwe-Kateera B, van de Wijgert J, Boer KR, Mukantwali E, Karita E, Gasengayire A, Jurriaans S, de Jong M, Ondoa P.

PLoS One. 2013 Aug 12;8(8):e64345. doi: 10.1371/journal.pone.0064345. eCollection 2013.

15.

Has the rate of CD4 cell count decline before initiation of antiretroviral therapy changed over the course of the Dutch HIV epidemic among MSM?

Gras L, Geskus RB, Jurriaans S, Bakker M, van Sighem A, Bezemer D, Fraser C, Prins JM, Berkhout B, de Wolf F; ATHENA National Observational Cohort.

PLoS One. 2013 May 27;8(5):e64437. doi: 10.1371/journal.pone.0064437. Print 2013.

16.

Oxygen and heterotrophy affect calcification of the scleractinian coral Galaxea fascicularis.

Wijgerde T, Jurriaans S, Hoofd M, Verreth JA, Osinga R.

PLoS One. 2012;7(12):e52702. doi: 10.1371/journal.pone.0052702. Epub 2012 Dec 21.

17.

Transmission of risk-group specific HIV-1 strains among Dutch drug users for more than 20 years and their replacement by nonspecific strains after switching to low-harm drug practices.

Lukashov VV, Jurriaans S, Bakker M, Berkhout B.

J Acquir Immune Defic Syndr. 2013 Feb 1;62(2):234-8. doi: 10.1097/QAI.0b013e318279734d.

PMID:
23117501
18.

Human immunodeficiency virus type 1 gp120 envelope characteristics associated with disease progression differ in family members infected with genetically similar viruses.

Baan E, van der Sluis RM, Bakker ME, Bekker V, Pajkrt D, Jurriaans S, Kuijpers TW, Berkhout B, Wolthers KC, Paxton WA, Pollakis G.

J Gen Virol. 2013 Jan;94(Pt 1):20-9. doi: 10.1099/vir.0.046185-0. Epub 2012 Sep 26.

PMID:
23015744
19.

Performance of VIDISCA-454 in feces-suspensions and serum.

de Vries M, Oude Munnink BB, Deijs M, Canuti M, Koekkoek SM, Molenkamp R, Bakker M, Jurriaans S, van Schaik BD, Luyf AC, Olabarriaga SD, van Kampen AH, van der Hoek L.

Viruses. 2012 Aug;4(8):1328-34. doi: 10.3390/v4081328. Epub 2012 Aug 22.

20.

Modest nonadherence to antiretroviral therapy promotes residual HIV-1 replication in the absence of virological rebound in plasma.

Pasternak AO, de Bruin M, Jurriaans S, Bakker M, Berkhout B, Prins JM, Lukashov VV.

J Infect Dis. 2012 Nov;206(9):1443-52. doi: 10.1093/infdis/jis502. Epub 2012 Aug 20.

PMID:
22927449
21.

Molecular and phylogeographic analysis of human immuno-deficiency virus type 1 strains infecting treatment-naive patients from Kigali, Rwanda.

Rusine J, Jurriaans S, van de Wijgert J, Cornelissen M, Kateera B, Boer K, Karita E, Mukabayire O, de Jong M, Ondoa P.

PLoS One. 2012;7(8):e42557. doi: 10.1371/journal.pone.0042557. Epub 2012 Aug 14.

22.

No treatment versus 24 or 60 weeks of antiretroviral treatment during primary HIV infection: the randomized Primo-SHM trial.

Grijsen ML, Steingrover R, Wit FW, Jurriaans S, Verbon A, Brinkman K, van der Ende ME, Soetekouw R, de Wolf F, Lange JM, Schuitemaker H, Prins JM; Primo-SHM Study Group.

PLoS Med. 2012;9(3):e1001196. doi: 10.1371/journal.pmed.1001196. Epub 2012 Mar 27.

23.

HIV-1 drug resistance in antiretroviral-naive individuals with HIV-1-associated tuberculous meningitis initiating antiretroviral therapy in Vietnam.

Thao VP, Le T, Török EM, Yen NT, Chau TT, Jurriaans S, van Doorn HR, de Jong MD, Farrar JJ, Dunstan SJ.

Antivir Ther. 2012;17(5):905-13. doi: 10.3851/IMP2092. Epub 2012 Mar 21. Erratum in: Antivir Ther. 2012;17(5):937. van Doorn, Rogier H [corrected to van Doorn, H Rogier].

PMID:
22473024
24.

HIV-1 dual infection is associated with faster CD4+ T-cell decline in a cohort of men with primary HIV infection.

Cornelissen M, Pasternak AO, Grijsen ML, Zorgdrager F, Bakker M, Blom P, Prins JM, Jurriaans S, van der Kuyl AC.

Clin Infect Dis. 2012 Feb 15;54(4):539-47. doi: 10.1093/cid/cir849. Epub 2011 Dec 9.

PMID:
22157174
25.

Ten years of HIV testing with fourth generation assays: the Amsterdam experience.

Jurriaans S, Back NK, Wolthers KC.

J Clin Virol. 2011 Dec;52 Suppl 1:S67-9. doi: 10.1016/j.jcv.2011.09.021. Epub 2011 Oct 12.

PMID:
21995933
26.

Transmission of two distinct HIV type 1 strains to an individual that were harbored for many years by another.

van Werkhoven MB, Baan E, Bakker M, Jurriaans S, Paxton WA, Pollakis G.

AIDS Res Hum Retroviruses. 2012 Feb;28(2):225-7. doi: 10.1089/aid.2011.0178. Epub 2011 Jul 26.

27.

Altered dynamics and differential infection profiles of lymphoid and myeloid cell subsets during acute and chronic HIV-1 infection.

Centlivre M, Legrand N, Steingrover R, van der Sluis R, Grijsen ML, Bakker M, Jurriaans S, Berkhout B, Paxton WA, Prins JM, Pollakis G.

J Leukoc Biol. 2011 May;89(5):785-95. doi: 10.1189/jlb.0410231. Epub 2011 Feb 10.

PMID:
21310820
28.

Ongoing HIV-1 transmission among men who have sex with men in Amsterdam: a 25-year prospective cohort study.

Jansen IA, Geskus RB, Davidovich U, Jurriaans S, Coutinho RA, Prins M, Stolte IG.

AIDS. 2011 Feb 20;25(4):493-501. doi: 10.1097/QAD.0b013e328342fbe9.

PMID:
21192230
29.

Unusual cluster of HIV type 1 dual infections in Groningen, The Netherlands.

van der Kuyl AC, Jurriaans S, Back NK, Sprenger HG, van der Werf TS, Zorgdrager F, Berkhout B, Cornelissen M.

AIDS Res Hum Retroviruses. 2011 Apr;27(4):429-33. doi: 10.1089/aid.2010.0175. Epub 2010 Nov 18.

PMID:
21087141
30.

Lack of detection of XMRV in seminal plasma from HIV-1 infected men in The Netherlands.

Cornelissen M, Zorgdrager F, Blom P, Jurriaans S, Repping S, van Leeuwen E, Bakker M, Berkhout B, van der Kuyl AC.

PLoS One. 2010 Aug 10;5(8):e12040. doi: 10.1371/journal.pone.0012040.

31.

Clinical significance of transient HIV type-1 viraemia and treatment interruptions during suppressive antiretroviral treatment.

Zhang S, van Sighem A, Gras L, Reiss P, Smit C, Kroon F, Jurriaans S, Prins J, Lange J, de Wolf F.

Antivir Ther. 2010;15(4):555-62. doi: 10.3851/IMP1564.

PMID:
20587848
32.

Steady increase in cellular HIV-1 load during the asymptomatic phase of untreated infection despite stable plasma viremia.

Pasternak AO, Jurriaans S, Bakker M, Berkhout B, Lukashov VV.

AIDS. 2010 Jul 17;24(11):1641-9. doi: 10.1097/QAD.0b013e32833b3171.

PMID:
20543660
33.

HIV RNA levels in transmission sources only weakly predict plasma viral load in recipients.

van der Kuyl AC, Jurriaans S, Pollakis G, Bakker M, Cornelissen M.

AIDS. 2010 Jun 19;24(10):1607-8. doi: 10.1097/QAD.0b013e32833b318f. No abstract available.

PMID:
20539098
34.

Cellular levels of HIV unspliced RNA from patients on combination antiretroviral therapy with undetectable plasma viremia predict the therapy outcome.

Pasternak AO, Jurriaans S, Bakker M, Prins JM, Berkhout B, Lukashov VV.

PLoS One. 2009 Dec 31;4(12):e8490. doi: 10.1371/journal.pone.0008490.

35.

Viral load levels measured at set-point have risen over the last decade of the HIV epidemic in the Netherlands.

Gras L, Jurriaans S, Bakker M, van Sighem A, Bezemer D, Fraser C, Lange J, Prins JM, Berkhout B, de Wolf F; ATHENA National Observational Cohort Study.

PLoS One. 2009 Oct 7;4(10):e7365. doi: 10.1371/journal.pone.0007365.

36.

Multiple transmissions of a stable human leucocyte antigen-B27 cytotoxic T-cell-escape strain of HIV-1 in The Netherlands.

Cornelissen M, Hoogland FM, Back NK, Jurriaans S, Zorgdrager F, Bakker M, Brinkman K, Prins M, van der Kuyl AC.

AIDS. 2009 Jul 31;23(12):1495-500. doi: 10.1097/QAD.0b013e32832d9267.

PMID:
19487902
37.

Incidence of human immunodeficiency virus type 1 dual infections in Amsterdam, The Netherlands, during 2003-2007.

van der Kuyl AC, Zorgdrager F, Jurriaans S, Back NK, Prins JM, Brinkman K, van Eeden A, Bakker M, Cornelissen M.

Clin Infect Dis. 2009 Apr 1;48(7):973-8. doi: 10.1086/597356.

PMID:
19231977
38.

High incidence of asymptomatic syphilis in HIV-infected MSM justifies routine screening.

Branger J, van der Meer JT, van Ketel RJ, Jurriaans S, Prins JM.

Sex Transm Dis. 2009 Feb;36(2):84-5. doi: 10.1097/OLQ.0b013e318186debb.

PMID:
18971797
39.

HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.

Steingrover R, Pogány K, Fernandez Garcia E, Jurriaans S, Brinkman K, Schuitemaker H, Miedema F, Lange JM, Prins JM.

AIDS. 2008 Aug 20;22(13):1583-8. doi: 10.1097/QAD.0b013e328305bd77.

PMID:
18670217
40.

Highly sensitive methods based on seminested real-time reverse transcription-PCR for quantitation of human immunodeficiency virus type 1 unspliced and multiply spliced RNA and proviral DNA.

Pasternak AO, Adema KW, Bakker M, Jurriaans S, Berkhout B, Cornelissen M, Lukashov VV.

J Clin Microbiol. 2008 Jul;46(7):2206-11. doi: 10.1128/JCM.00055-08. Epub 2008 May 7.

41.

Intravenous immunoglobulin (IVIG) treatment for modulation of immune activation in human immunodeficiency virus type 1 infected therapy-naive individuals.

Vermeulen JN, Prins JM, Bunnik E, Hack CE, Jurriaans S, Miedema F, Lange JM, Schuitemaker H.

AIDS Res Hum Retroviruses. 2007 Nov;23(11):1348-53. doi: 10.1089/aid.2006.0210.

PMID:
18184076
42.

Combination antiretroviral therapy failure and HIV super-infection.

Bezemer D, van Sighem A, de Wolf F, Cornelissen M, van der Kuyl AC, Jurriaans S, van der Hoek L, Prins M, Coutinho RA, Lukashov VV.

AIDS. 2008 Jan 11;22(2):309-11.

PMID:
18097235
43.

A sudden rise in viral load is infrequently associated with HIV-1 superinfection.

Jurriaans S, Kozaczynska K, Zorgdrager F, Steingrover R, Prins JM, van der Kuyl AC, Cornelissen M.

J Acquir Immune Defic Syndr. 2008 Jan 1;47(1):69-73.

PMID:
17891042
44.

Increase in HCV incidence among men who have sex with men in Amsterdam most likely caused by sexual transmission.

van de Laar TJ, van der Bij AK, Prins M, Bruisten SM, Brinkman K, Ruys TA, van der Meer JT, de Vries HJ, Mulder JW, van Agtmael M, Jurriaans S, Wolthers KC, Coutinho RA.

J Infect Dis. 2007 Jul 15;196(2):230-8. Epub 2007 Jun 11.

PMID:
17570110
45.

Routine HIV-1 genotyping as a tool to identify dual infections.

Cornelissen M, Jurriaans S, Kozaczynska K, Prins JM, Hamidjaja RA, Zorgdrager F, Bakker M, Back N, van der Kuyl AC.

AIDS. 2007 Apr 23;21(7):807-11.

PMID:
17415035
46.

Characterization of an HIV-1 group M variant that is distinct from the known subtypes.

van der Hoek L, Pollakis G, Lukashov VV, Jebbink MF, Jeeninga RE, Bakker M, Dukers N, Jurriaans S, Paxton WA, Back NK, Berkhout B.

AIDS Res Hum Retroviruses. 2007 Mar;23(3):466-70.

PMID:
17411380
47.

Major decline of hepatitis C virus incidence rate over two decades in a cohort of drug users.

van den Berg CH, Smit C, Bakker M, Geskus RB, Berkhout B, Jurriaans S, Coutinho RA, Wolthers KC, Prins M.

Eur J Epidemiol. 2007;22(3):183-93. Epub 2007 Mar 3.

48.

Once-daily highly active antiretroviral therapy for HIV-infected children: safety and efficacy of an efavirenz-containing regimen.

Scherpbier HJ, Bekker V, Pajkrt D, Jurriaans S, Lange JM, Kuijpers TW.

Pediatrics. 2007 Mar;119(3):e705-15. Epub 2007 Feb 16.

PMID:
17308244
49.

HIV incidence and HIV testing behavior in men who have sex with men: using three incidence sources, The Netherlands, 1984-2005.

Dukers NH, Fennema HS, van der Snoek EM, Krol A, Geskus RB, Pospiech M, Jurriaans S, van der Meijden WI, Coutinho RA, Prins M.

AIDS. 2007 Feb 19;21(4):491-9.

PMID:
17301568
50.

Antiviral activity of HIV type 1 protease inhibitors nelfinavir and indinavir in vivo is not influenced by P-glycoprotein activity on CD4+ T cells.

Sankatsing SU, Cornelissen M, Kloosterboer N, Crommentuyn KM, Bosch TM, Mul FP, Jurriaans S, Huitema AD, Beijnen JH, Lange JM, Prins JM, Schuitemaker H.

AIDS Res Hum Retroviruses. 2007 Jan;23(1):19-27.

PMID:
17263628

Supplemental Content

Loading ...
Support Center